2nd Patient to Get Foralumab Nasal Spray After Promising First Data

2nd Patient to Get Foralumab Nasal Spray After Promising First Data

315915

2nd Patient to Get Foralumab Nasal Spray After Promising First Data

Following promising data from the first participant in a special access program that’s testing foralumab nasal spray for secondary progressive multiple sclerosis (SPMS), a second patient has been enrolled in the ongoing evaluation. The first patient in the study, by Tiziana Life Sciences, the nasal spray’s developer, was halfway through the course of treatment, and early data indicated that foralumab was well-tolerated and effective, the company said. The new enrollment was authorized by the U.S. Food and Drug…

You must be logged in to read/download the full post.